Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

Osteosarcoma

Neoplasm Metastasis

Urinary Bladder Neoplasms

Neoplasm Metastasis, Prostatic Neoplasms

Breast Neoplasms

Endometrial Neoplasms

Breast Neoplasms

Neoplasm Metastasis, Carcinoma, Merkel Cell

Carcinoma, Transitional Cell

Lymphoma, Lymphoma, Follicular

Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections

Carcinoma, Non-Small-Cell Lung, Neoplasms

Metastatic Castration-resistant Prostate Cancer

Urinary Bladder Neoplasms

Adenocarcinoma Of Esophagus, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Mesothelioma, Malignant

Leukemia, Myeloid, Acute

Carcinoma, Hepatocellular

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

Metastatic Urothelial Cell Cancer

Parkinson Disease 4, Autosomal Dominant Lewy Body, Glioblastoma, Glioma

Leiomyosarcoma, Liposarcoma

Adenocarcinoma

Carcinoma, Merkel Cell

Prostatic Neoplasms

Fallopian Tube Neoplasms

Leukemia, Myeloid, Acute

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Pancreatic Cancer Resectable

Clinical Trials

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Avelumab and Radiation in Muscle-Invasive Bladder Cancer

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Palbociclib After CDK and Endocrine Therapy (PACE)

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma

Rituximab + Immunotherapy in Follicular Lymphoma

Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

AVAIL-T

Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC

OU-SCC-ABC

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

SPRING

Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients

Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

PICK-NEPC

Anti-PD-L1 and SAbR for Ovarian Cancer

Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer

17-134